Breaking Barriers in James’s Fight with Acute Myeloid Leukemia

When James was 7 weeks old, his parents noticed unusual bruising and spots on his tiny skin and dismissed them at first as newborn quirks. A fever changed everything and sent them to the ER. There, abnormal white blood cell counts revealed acute myeloid leukemia (AML), upending their lives forever. Within hours, they relocated to a hospital with the resources to fight for him.

Over six months, James endured bone marrow biopsies and chemotherapy, his condition swinging wildly. By 9 months, his family “rang the bell” marking the end of his first battle. Holidays at home proceeded until a spot on his eye signaled relapse. Eighteen months later, dizziness, vomiting, and loss of balance brought more devastating news: AML had returned, now with a central nervous system tumor.

They relocated again to a different hospital, Stanford Medical Center, where he could receive an experimental, non-FDA-approved treatment to inhibit tumor growth, successful in 2 of 10 patients. James was among the fortunate, alongside a second bone marrow transplant, multiple transfers, emotional exhaustion, and financial strain that tested his family. From Orangeville, a small town near Sacramento, they faced $261,164 in estimated costs (insurance-covered), far above the national average of $160,000 for pediatric AML, with $10,000 -$20,000 out-of-pocket.

James's story haunts us for the barriers his family surmounted but the development of new treatments and his recovery give us hope. Early diagnosis was permitted by multiple blood draws and biopsies that are invasive. Dr. Zhang's lab at Stanford's Cancer Research Center pursues liquid biopsies using circulating tumor DNA from a single blood draw to monitor AML less intrusively. "This could replace bone marrow procedures [like James's]," she told us, "getting patients screened earlier in their journey."

However, access tells a starker tale. Dr. Krutika Kuppalli, working with the World Health Organization in Ethiopia, drew parallels: "If somebody lacks financial resources, medications become a severe burden." Jennice Wong, a Stanford Oncology social worker, echoed this locally: "Our healthcare system is disappointingly confusing. Most patients I see don't know how to access insurance or resources especially when relocating to specialized centers."

James survived two rounds of AML and a transplant. Recently discharged, he recovers nearby. His "happy ending" underscores progress from clinical trials and targeted therapies but not equity. Programs like Medicaid help, yet non-medical costs and global disparities persist. Families without his luck face helplessness.

Witnessing James's fight crystallized my commitment to health professions research. As medical journalists, we saw how privilege in geography, insurance, and experts proximity, tilt survival odds. AML is fast-growing from bone marrow to blood, disrupts myeloid cells, causing fatigue, infections, bruising. Treatment has evolved, but the human cost lingers: families uprooted and for some, inequities unyielding.

James's fight revealed how medicine's successes teeter without broader reform. While grants, community aid, and advancements like liquid biopsies help, they aren't enough. We must dismantle the economic and locational hurdles that bar families from vital care. His bell-ringing smile reminds us why every child deserves the same chance.

Patient details are anonymized to protect privacy. Acknowledgments to Michael Nedelman, for mentorship.